Eberlein T J, Rosenstein M, Spiess P J, Rosenberg S A
J Natl Cancer Inst. 1982 Jul;69(1):109-16.
The long-term in vitro growth in T-cell growth factor (TCGF) of murine cytotoxic T-lymphoid cells directed against syngeneic tumor antigens was investigated. C57BL/6 mice were immunized to syngeneic FBL-3 lymphoma by two ip injections of irradiated FBL-3 lymphoma cells. Splenocytes from these animals were injected into mice with disseminated lethal FBL-3 tumor. The injection of cyclophosphamide (Cy) plus immunized lymphocytes significantly improved survival with cure of 53% of 38 animals. In comparison, treatment with Cy alone resulted in 0 of 31 cured and treatment with Cy plus unimmunized cells resulted in 0 of 40 cured (P less than 0.0005). These in vivo immunized lymphocytes were reexposed to FBL-3 tumor in vitro for 5 days in lectin-free TCGF (LF-TCGF). Although in vivo and in vitro sensitized lymphocytes exhibited no cytotoxicity toward fresh FBL-3 tumor cells in an 18-hour 51Cr release assay, expansion of appropriately sensitized cells in LF-TCGF resulted in significant lysis of fresh FBL-3 tumor cells. This significant lysis was specific and lysed syngeneic FBL-3 but not syngeneic MCA-103 fresh tumor targets. This maximal specific cytotoxicity was maintained for 2.5 months. A screening assay was developed that permitted rapid identification and isolation of low-frequency cytotoxic clones with reactivity specific for FBL-3 tumor. Several of these cloned cells were grown for almost 3 months with maintenance of high degrees of specific lysis (as much as 4,500 lytic U/10(6) cells). These cytotoxic lines and clones will be of value for the study of tumor-host immunologic interactions and perhaps for use in adoptive immunotherapy.
研究了针对同基因肿瘤抗原的小鼠细胞毒性T淋巴细胞在T细胞生长因子(TCGF)中的长期体外生长情况。通过腹腔注射两次经照射的FBL-3淋巴瘤细胞,使C57BL/6小鼠对同基因FBL-3淋巴瘤产生免疫。将这些动物的脾细胞注射到患有播散性致死性FBL-3肿瘤的小鼠体内。注射环磷酰胺(Cy)加免疫淋巴细胞可显著提高生存率,38只动物中有53%被治愈。相比之下,单独使用Cy治疗31只动物无一治愈,使用Cy加未免疫细胞治疗40只动物也无一治愈(P<0.0005)。将这些体内免疫的淋巴细胞在无凝集素的TCGF(LF-TCGF)中于体外再次暴露于FBL-3肿瘤5天。尽管在18小时的51Cr释放试验中,体内和体外致敏的淋巴细胞对新鲜FBL-3肿瘤细胞均无细胞毒性,但在LF-TCGF中适当致敏细胞的扩增导致了对新鲜FBL-3肿瘤细胞的显著裂解。这种显著的裂解具有特异性,可裂解同基因FBL-3但不能裂解同基因MCA-103新鲜肿瘤靶细胞。这种最大特异性细胞毒性维持了2.5个月。开发了一种筛选试验,可快速鉴定和分离对FBL-3肿瘤具有特异性反应性的低频细胞毒性克隆。其中几个克隆细胞生长了近3个月,仍保持高度的特异性裂解(高达4500裂解单位/10(6)细胞)。这些细胞毒性系和克隆对于研究肿瘤-宿主免疫相互作用可能有价值,也许还可用于过继性免疫治疗。